PetMed Express (PETS)
(Delayed Data from NSDQ)
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
Zacks News
Falling Earnings Estimates Signal Weakness Ahead for Expedia (EXPE)
by Zacks Equity Research
Expedia (EXPE) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
NuVasive Gains From International Business Amid Pricing Woes
by Zacks Equity Research
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors
Amazon CEO Tops Forbes Rich List, Shares Hit 52-Week High
by Zacks Equity Research
Amazon (AMZN) attains 52-week high on AWS strength and diversified presence. Meanwhile, CEO Jeff Bezos tops Forbes Rich List for the first time.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Allscripts (MDRX) Launches Avenel to Revamp EHR Platform
by Zacks Equity Research
Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Abaxis Banks on Strong Veterinary Business Amid Margin Woes
by Zacks Equity Research
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.
3 Reasons Why You Should Invest in athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) rides on solid fourth-quarter results and strong fundamentals.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
BioTelemetry (BEAT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) sees strong Q4 results, courtesy of solid acquisitions and promising performance by the MCT platform.
eBay's (EBAY) Marketplace is Expected to Do Well in 2018
by Zacks Equity Research
eBay (EBAY) is making all efforts to improve its Marketplace business.
JD.com (JD) Q4 Earnings Miss Estimates, Revenues Improve Y/Y
by Zacks Equity Research
JD.com's (JD) fourth-quarter earnings are impacted by higher spending in growth areas including fulfillment centers and increasing competition from Alibaba.
Bio-Rad (BIO) Q4 Earnings Improve Y/Y, Revenues Top Mark
by Zacks Equity Research
Bio-Rad's (BIO) strong sales in Q4 ride high on a robust performance at Life Science product lines.
OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.
Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View
by Zacks Equity Research
Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.
Alarm.com (ALRM) Q4 Earnings Top Estimates, Issues 2018 View
by Zacks Equity Research
Alarm.com (ALRM) reports strong fourth-quarter results on the back of higher SaaS and license revenues, and portfolio expansion.
Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive
by Zacks Equity Research
Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.
DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
DexCom (DXCM) rides high on strength in all segments in Q4.
Wright Medical (WMGI) Beats Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Wright Medical (WMGI) delivers promising Q4 results on the back of strength in its flagship Upper Extremities segment, despite declining international revenues of the Lower Extremities.
Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Amedisys (AMED) registers strong growth across all segments in Q4.
Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) sees strong growth across all geographical regions and product lines in Q4.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Inogen (INGN) reports impressive Q4 financial results on the back of strong business-to-business and direct-to-consumer sales growth.